Verrucarin J (Muconomycin B) is a metabolite of the Myrothecium fungus family. Verrucarin J generates reactive oxygen species ( ROS ) and induces apoptosis of cancer cell lines, such as A549, HCT 116 and SW-620 cells. Verrucarin J shows activities against Candida albicans and Mucor miehei. Verrucarin J inhibits arenavirus Junin (JUNV) yield with an IC 50 of 1.2 ng/mL. In Vitro Verrucarin J (0, 5, 10, 20, 50 nM; 24 hours) induces the apoptosis of A549 cells. Verrucarin J (0, 1, 2, 5, 10, 20, 50 nM; 24, 48, 72 hours) significantly inhibits cell proliferation of A549 and H1793 cells with IC 50 values of approximately 10 nM and 20 nM after 48 h of treatment, respectively. Verrucarin J (0, 0.1, 0.2, 0.3, 0.4, 0.5 μM; 24 hours) has an IC 50 of 300 nM for HCT 116 and SW-620 cell proliferation. Verrucarin J (0, 10, 20 nM, 48 hours) inhibits cancer stem cell (CSC) self-renewal pathways Wnt1/β-catenin and Notch1 and down-regulates the expression of key CSC specific genes (ALDH1, LGR5, OCT4 and CD133) of A549 cells. Verrucarin J (compound 2; 50 μg/disk) shows noteworthy activities against Candida albicans and Mucor miehei. Verrucarin J reduces JUNV yield more than 2 log units and has a similar effect against the arenavirus Tacaribe . Verrucarin J reduces the cell viability of Vero cells with a cytotoxic concentration 50%\n(CC 50 ) of 8.2 ng/mL . MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo Verrucarin J (0.5 mg/kg; i.p. for 4 weeks) suppresses AKT-induced tumor growth in a xenograft model. Verrucarin J (0.1, 0.5, 2.0 mg/kg; i.p. for three weeks) is a highly potent anticancer drug and suppresses tumor growth and metastasis. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: 6-8 weeks old BALB/c athymic nude mice (nu/nu) with pCMV/HCT 116 and AKT/HCT 116 xenograftsDosage: 0.5 mg/kg body weight Administration: i.p. for 4 weeks Result: Reduced the expression of prosurvival markers pAKT, Notch1, p65, and Ki67 in all tumors. Animal Model: Female nude nu/nu (5 to 6 weeks old) mice with A2780 xenograftsDosage: 0.1, 0.5, 2.0 mg/kg (vehicle: 10% DMSO, 90% glyceryl trioctanoate) Administration: i.p. for three weeks after 10 days of injection of A2780 cells Result: Reduced tumor weight (32% lower compared to control), and reduced visible metastasis in 0.1 mg/kg. Showed a significant reduction in visible peritoneal tumors (61% lower compared to control group) and highly reduced visible metastasis in 0.5 mg/kg. Reduced ovarian tumor weight by 71% compared to vehicle in 0.5 mg/kg. In lethal dose 2 mg/kg, mice sick with a swollen belly, body fluid and subsequently died within 3 treatments. Form:Solid